Dr. Schuster on Long-Term Outcomes of Lenalidomide and Rituximab in MCL

Stephen J. Schuster, MD
Published: Wednesday, Mar 07, 2018



Stephen J. Schuster, MD, professor of hematology/oncology at the University of Pennsylvania Abramson Cancer Center, discusses long-term outcomes of lenalidomide (Revlimid) and rituximab (Rituxan) in mantle cell lymphoma (MCL).

In a study of long-term outcomes of lenalidomide and rituximab in rituximab-resistant patients with indolent MCL and B-cell lymphomas, investigators sought to re-sensitize patients to rituximab. These are patients who have generally had multiple prior therapies without a successful outcome, says Schuster, and once a patient become refractory to rituximab, it is difficult to treat them with any other agent successfully.

Laboratory data suggest that the immunomodulatory properties of lenalidomide may be able to reverse immunosuppression. These long-term results showed that lenalidomide did reverse regulatory T cells, and patients responded to rituximab. Additionally, 25% of these patients remain in remission.


Stephen J. Schuster, MD, professor of hematology/oncology at the University of Pennsylvania Abramson Cancer Center, discusses long-term outcomes of lenalidomide (Revlimid) and rituximab (Rituxan) in mantle cell lymphoma (MCL).

In a study of long-term outcomes of lenalidomide and rituximab in rituximab-resistant patients with indolent MCL and B-cell lymphomas, investigators sought to re-sensitize patients to rituximab. These are patients who have generally had multiple prior therapies without a successful outcome, says Schuster, and once a patient become refractory to rituximab, it is difficult to treat them with any other agent successfully.

Laboratory data suggest that the immunomodulatory properties of lenalidomide may be able to reverse immunosuppression. These long-term results showed that lenalidomide did reverse regulatory T cells, and patients responded to rituximab. Additionally, 25% of these patients remain in remission.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x